Home IPHASE DS8201a

IPHASE DS8201a

ʻO ka wehewehe pōkole:

DS-8201a, also known as trastuzumab deruxtecan (T-DXd), is an antibody-drug conjugate (ADC) designed for the treatment of HER2-positive cancers. It combines a HER2-targeting monoclonal antibody (similar to trastuzumab) with a potent topoisomerase I inhibitor (deruxtecan) as the cytotoxic payload. The drug delivers chemotherapy directly to cancer cells expressing HER2, improving efficacy while limiting damage to normal cells.

E HOAKAKA NEI Hoʻohui i ke kaʻa kūʻai

Huahana Huahana

wehewehe huahana ʻO DS-8201a, i kapa ʻia ʻo trastuzumab deruxtecan (T-DXd), he antibody-drug conjugate (ADC) i hoʻolālā ʻia no ka mālama ʻana i ka HER2-mau maʻi maʻi maʻi. Hoʻohui ia i kahi antibody monoclonal HER2-targeting (like me trastuzumab) me kahi mea hoʻopaneʻe topoisomerase I ikaika (deruxtecan) ma ke ʻano he cytotoxic payload. Hāʻawi pololei ka lāʻau lapaʻau i ka chemotherapy i nā maʻi maʻi maʻi e hōʻike ana i ka HER2, e hoʻomaikaʻi ana i ka pono ʻoiai e kaupalena ana i ka pōʻino i nā cell maʻamau.

Māhele:
Cathepsin
'ikamu NO.:
015200.01
Lahi Unit:
50uL,2mg/mL
Tissue:
N/A
ʻano:
N/A
Nā kūlana mālama a me ka lawe ʻana:
E kūʻai ma -70°C. Hāʻawi ʻia ka hau maloʻo.